Liquid biopsy in the management of solid tumours

The inherent limitations of using tumour tissues for genomic profiling has led to the need for a more efficient, easily accessible yet accurate method of evaluating biomarkers to facilitate personalised medicine. At the ESMO Asia Colloquia chaired by Professor Byoung Chul Cho of Yonsei Cancer Centre, experts in the field of precision oncology shared insights on the diagnostic, prognostic and predictive values of tumour-derived blood biomarkers (liquid biopsy) for the management of various cancer types.